Have a feature idea you'd love to see implemented?
Let us know!
OTLK Outlook Therapeutics Inc
Price (delayed)
$5.13
Market cap
$121.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.9
Enterprise value
$122.05M
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME
Highlights
Outlook Therapeutics's equity has increased by 38% QoQ
OTLK's debt is down by 27% since the previous quarter and by 6% year-on-year
The EPS has plunged by 60% YoY but it has grown by 31% from the previous quarter
The net income has plunged by 56% YoY but it has grown by 41% from the previous quarter
Key stats
What are the main financial stats of OTLK
Market
Valuations
Earnings
Shares outstanding
23.66M
Market cap
$121.35M
Enterprise value
$122.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$91.46M
EBITDA
-$91.36M
Free cash flow
-$64.55M
Per share
Balance sheet
Liquidity
EPS
-$7.9
Free cash flow per share
-$2.78
Book value per share
-$3.57
Revenue per share
$0
TBVPS
$2.03
Total assets
$47.09M
Total liabilities
$130.77M
Debt
$32.72M
Equity
-$83.67M
Working capital
$3.06M
Debt to equity
-0.39
Current ratio
1.07
Quick ratio
0.75
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-235%
Return on equity
N/A
Return on invested capital
-4,985.1%
Return on capital employed
-2,015.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OTLK stock price
How has the Outlook Therapeutics stock price performed over time
Intraday
-2.84%
1 week
-6.9%
1 month
-9.84%
1 year
-40.28%
YTD
-34.9%
QTD
-3.93%
Financial performance
How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.28M
Net income
-$94.05M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 56% YoY but it has grown by 41% from the previous quarter
OTLK's operating income is down by 12% YoY and by 2.4% QoQ
Growth
What is Outlook Therapeutics's growth rate over time
Valuation
What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 60% YoY but it has grown by 31% from the previous quarter
Outlook Therapeutics's equity has increased by 38% QoQ
Efficiency
How efficient is Outlook Therapeutics business performance
The company's return on assets has shrunk by 85% YoY but it rose by 42% QoQ
Dividends
What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OTLK.
Financial health
How did Outlook Therapeutics financials performed over time
OTLK's total assets is 64% smaller than its total liabilities
OTLK's total liabilities has surged by 162% year-on-year but it is down by 32% since the previous quarter
The current ratio has grown by 24% YoY
OTLK's debt is 139% greater than its equity
OTLK's debt to equity has surged by 94% year-on-year but it is down by 18% since the previous quarter
Outlook Therapeutics's equity has increased by 38% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.